Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Vanguard S&P 500 Growth Index Fund ETF trades at $84.4 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 9.5× Dyne Therapeutics Inc. Common Stock's market cap, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Vanguard S&P 500 Growth Index Fund ETF for 56 Days on average.
| DYN | VOOG | |
|---|---|---|
Market Cap | $2.86B | $27.10B |
Volume | 3,341,579 | 775,650 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $87.81 |
52-Week Low | $14.60 | $65.32 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VOOG trades at $86.9, down slightly by 0.02% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking S&P 500 growth stocks, has seen strong institutional buying and positive media coverage highlighting its long-term growth potential and low expense ratio of 0.07%.
The outlook remains favorable for growth-oriented investors, supported by historical outperformance and sector concentration in technology. Key risks include market volatility and reliance on mega-cap tech stocks, but analyst sentiment and institutional inflows suggest continued confidence in its strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
